Mahkam Zanganeh bought $5.9M of Summit Therapeutics (SMMT)
Executed Sep 10 2025, disclosed Sep 11 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Sep 11 2025), the stock returned +27.4% (delay-adjusted); from the execution session (Sep 10 2025), +33.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Mahkam Zanganeh (Co-Chief Executive Officer) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in Summit Therapeutics Inc. (SMMT). Across 3 priced purchase filings, the average 21-session return was +3.3% from execution and +4.0% from disclosure (delay-adjusted; derived). The largest single filing was $50.0M of SMMT (3,810,000 sh × $13.12, as filed), executed Jun 12.
Healthcare · Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, care…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→3,810,000 sh × $13.12
Exec Jun 12
Filed Jun 12 · 2:35 PM ET SMMTPURCHASE Summit Therapeutics Inc. $1.5M
100,000 sh × $14.60
Exec Jun 4
Filed Jun 4 · 5:45 PM ET SMMTPURCHASE Summit Therapeutics Inc. $500K
26,680 sh × $18.74
Exec Oct 21 2025
Filed Oct 23 2025 · 4:06 PM ET